Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  dacarbazine
Find trials that include:  Any drugs shown
Results 1-10 of 10 for your search:
Start Over
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: C25003, NCI-2012-03101, 12/LO/1950, 2011-005450-60, JapicCTI-142491, U1111-1161-4937, NCT01712490
PV-10 Intralesional Injection vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PV-10-MM-31, NCI-2015-00568, NCT02288897
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with Stage II-IV HIV-Associated Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AMC-085, NCI-2013-00046, 085, 2014-003678-18, PAMC-085_A05PAMDREVW01, NCT01771107
Response-Based Therapy Assessed by PET Scan in Treating Patients with Stage I or Stage II Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 to 60
Trial IDs: CALGB 50801, NCI-2011-02034, CDR0000669076, NCT01118026
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients with Previously Untreated Stage II-IV Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: NU 11H01, NCI-2011-00684, NCT01476410
Combination Chemotherapy and Brentuximab Vedotin in Treating Patients with Stage I-II Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 60
Trial IDs: LCCC 1115, NCI-2013-00975, 12-0303, NCT01578967
Cabozantinib-S-Malate Compared with Temozolomide or Dacarbazine in Treating Patients with Melanoma of the Eye
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091201, NCI-2013-00821, CALGB-A091201, NCT01835145
Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients with Stage IIB-IVB Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 and under
Trial IDs: HLHR13, NCI-2013-01123, NCT01920932
Brentuximab Vedotin, Combination Chemotherapy, and Radiation Therapy in Treating Patients with Newly Diagnosed, Early Stage, Unfavorable-Risk Hodgkin Lymphoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 to 60
Trial IDs: 13-034, NCI-2013-01144, NCT01868451
Start Over